Taysha Gene Therapies (TSHA) Free Cash Flow (2020 - 2026)
Taysha Gene Therapies (TSHA) reported Free Cash Flow of -$40.9 million for Q1 2026, down 85.56% on a YoY basis from -$283.2 million in Q1 2025, and down 49.09% sequentially from -$27.4 million in Q4 2025.
Taysha Gene Therapies (TSHA) Free Cash Flow (2020 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 7 years of Free Cash Flow data on file, last reported at -$40.9 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 85.56% year-over-year to -$40.9 million; the trailing twelve-month figure through Mar 2026 stood at -$112.7 million (down 34.63% YoY), and the FY2025 full-year result was -$93.8 million, down 14.99% from the prior year.
- Free Cash Flow slipped to -$40.9 million in Q1 2026, from -$27.4 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$5.9 million in Q4 2022 to a low of -$41.0 million in Q1 2022.
- A 5-year average of -$23.7 million and a median of -$21.8 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow surged 87.91% in 2022 and tumbled 233.44% in 2023, its largest moves.
- Tracing TSHA's Free Cash Flow over 5 years: stood at -$5.9 million in 2022, then plunged by 233.44% to -$19.6 million in 2023, then rose by 6.43% to -$18.3 million in 2024, then tumbled by 49.87% to -$27.4 million in 2025, then tumbled by 49.09% to -$40.9 million in 2026.
- Business Quant data shows TSHA's Free Cash Flow at -$40.9 million in Q1 2026, -$27.4 million in Q4 2025, and -$23.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - | -40.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.90 Mn |
| Mar 31, 2026 | -40.90 Mn |
| Dec 31, 2025 | -27.44 Mn |
| Dec 31, 2025 | -27.44 Mn |
| Sep 30, 2025 | -23.78 Mn |
| Sep 30, 2025 | -23.78 Mn |
| Jun 30, 2025 | -20.57 Mn |
| Jun 30, 2025 | -20.57 Mn |
| Mar 31, 2025 | -22.04 Mn |
| Mar 31, 2025 | -22.04 Mn |
| Dec 31, 2024 | -18.31 Mn |
| Dec 31, 2024 | -18.31 Mn |
| Sep 30, 2024 | -21.55 Mn |
| Sep 30, 2024 | -21.55 Mn |
| Jun 30, 2024 | -21.81 Mn |
| Jun 30, 2024 | -21.81 Mn |
| Mar 31, 2024 | -19.94 Mn |
| Mar 31, 2024 | -19.94 Mn |
| Dec 31, 2023 | -19.56 Mn |
| Dec 31, 2023 | -19.56 Mn |